ASPH and neoplasm: Additionally, as ASPH was identified as a tumor-associated antigen, immunotherapy approaches, vaccines and monoclonal antibodies, were tested with promising results in preclinical experiments and results of phase I clinical trial with the PAN-301-1 vaccine were published [100].